Bepotastine

Bepotastine

Clinical data
Trade names	Bepreve
AHFS/Drugs.com	International Drug Names
MedlinePlus	a610012
Routes of administration	Oral, eye drops
ATC code	none
Legal status
Legal status	CA: ℞-only[1] In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	High (oral) Minimal (topical)
Protein binding	~55%
Excretion	Renal (75–85
Identifiers
IUPAC name 4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
CAS Number	125602-71-3 N
PubChem CID	2350
DrugBank	DB04890 Y
ChemSpider	2260 Y
UNII	HYD2U48IAS
KEGG	D09705 Y
ChEBI	CHEBI:71204 N
ChEMBL	ChEMBL1201758 N
CompTox Dashboard (EPA)	DTXSID90904947
Chemical and physical data
Formula	C21H25ClN2O3
Molar mass	388.89 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1)C(OC2CCN(CCCC(=O)O)CC2)c3ncccc3
InChI InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26) Y Key:YWGDOWXRIALTES-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Bepotastine (Talion, Bepreve) is a 2nd generation antihistamine.^[2] It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000, and January 2002, respectively. It is marketed in the United States as an eye drop under the brand name Bepreve, by ISTA Pharmaceuticals, a subsidiary of Bausch + Lomb.^{[citation needed]}